Navigation Links
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Date:3/20/2008

cal trials, two of which, atazanavir for HIV, and entecavir for Hepatitis B, are currently approved drugs."

Ron Bentsur, XTL's CEO commented: "We are excited about this licensing transaction with a motivated and capable partner such as Presidio. This transaction allows us to solidify our financial position by bringing in $4 million dollars in cash and eliminating the ongoing development expense of the Program, while preserving a significant share in the Program's future success. We believe that this transaction extends our financial resources well into Q1 2009, and provides us with a financial cushion as we head towards the completion and announcement of results from the Bicifadine Phase 2b study, expected in Q4 2008."

The Program focuses on the development of novel small molecule inhibitors against the Hepatitis C virus, and is presently in advanced stages of lead optimization. The current lead compounds target NS5A - a viral protein that is essential for viral production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of the Hepatitis C Virus.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
(Date:9/18/2014)... Scientists at USC have developed a new microscopy ... in living animals at higher-than-ever resolution. , Dubbed ... allows imaging resolutions that are an order of ... insights into the behavior of biomolecules at the ... Sept. 18 by Nature Communications , the ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/18/2014)... Whitehouse Laboratories is pleased to announce that ... has acquired an additional 4,000 square feet of dedicated ... adjacent to its current package testing facility. The official ... Whitehouse Labs is in the process of upgrading the ... testing. The prime location enables Whitehouse Labs to immediately ...
Breaking Biology Technology:Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... of Pittsburgh School of Dental Medicine are piecing together ... to novel nanoscale approaches to developing biomaterials. The findings ... of the National Academy of Sciences . Dental ... and combines high hardness with resilience, said Elia Beniash, ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... focus on cell based therapeutics development, today announced that ... Program (PRMRP) of the Office of the Congressionally Directed ... be applied towards funding the Company,s VSEL™ Technology. This ...
... testing within the pharmaceutical and cosmetic industries and companies ... their products are safe to use. Research published in ... demonstrates that the response of laboratory grown human cells ... or non-sensitizing, and can even predict the strength of ...
Cached Biology Technology:NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 2NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 3NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 4Cell-based alternative to animal testing 2
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... obtained the first partial genome sequence of an ancient ... the site of the Montsoriu Castle in Girona, the ... related to today,s Iberian pig. Researchers also discard the ... pigs. , The study, published in Heredity , ... and particularly on that of the Iberian breed, considered ...
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2
... North Grafton, Mass., August 10, 2011 Second graders ... to maintain their reading skills during the dog days of ... Cummings School of Veterinary Medicine at Tufts University. In ... second-grade students with a range of reading aptitudes and attitudes ...
... structure of a complex formed when a protein binds ... how an antibiotic-producing organism controls resistance to its own ... antibiotic producers regulate export to prevent self-toxicity. , The ... complex and highly regulated process, not least because the ...
... , Invasive species cost an estimated $1.4 trillion annually ... second only to habitat loss as a threat to ... invasive species, the question of why some species are ... Dr. Alison Bennett and Dr. Sharon Strauss at the ...
Cached Biology News:Days spent reading to dogs during summer may help avoid decline of reading skills 2Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3Waging war on invasive plant species: Effects of invasives persist even after removal 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... DeCypher combines enterprise-scale sequence analysis software with the ... analyses. With DeCypher, you can perform searches like ... vs NCBI NT database in under 6 days ... genomic DNA Use HMM analysis to ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: